精神分裂症(面向对象编程)
抗精神病药
胆碱能的
医学
安慰剂
副作用(计算机科学)
精神病
精神科
心理学
内科学
计算机科学
病理
程序设计语言
替代医学
作者
John Cookson,Ferdinand Jonsson
出处
期刊:The Lancet
[Elsevier]
日期:2022-12-01
卷期号:400 (10369): 2159-2161
标识
DOI:10.1016/s0140-6736(22)02421-7
摘要
Existing antipsychotic medicines have impressive effectiveness in treating acute episodes of schizophrenia and preventing relapses, providing enormous impact for many patients. However, they are associated with short-term and longer-term side-effects, and their effects are directed mainly at hallucinations, delusions, and disorganised thinking. Patients are left with residual so-called negative symptoms, most notably loss of motivation and cognitive difficulties that contribute to substantial functional impairments. Additionally, up to one-third of people with schizophrenia do not reach symptomatic remission with antipsychotic medicines. Therefore, new antipsychotic agents, with greater efficacy or fewer side-effects, are now required. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trialThese data support further investigation of emraclidine as a once-daily treatment for schizophrenia without need for titration and with a potentially favourable side-effect profile. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI